Plan for Long Haul, Analyst Warns
Vital Therapies Files $86M IPO; Cycle ‘Sure To Turn,’ but When?
By Randy Osborne
Staff Writer
Staff Writer
“Caveat emptor” is a warning hardly needed by seasoned investors in biotech, many of whom understand the failure-fraught industry and are cautious buyers, when they can be persuaded to buy at all.
